Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BPR277 ointment (controlled application)
BPR277 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Cohort A and B, BPR277 and Placebo (vehicle) | EXPERIMENTAL | - |
| Part 2 BPR277 | EXPERIMENTAL | - |
| Part 2 Placebo (vehicle) | PLACEBO_COMPARATOR | - |
| Part 3 BPR277 and Placebo (vehicle) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BPR277 ointment (controlled application) | DRUG | - |
| Placebo (Vehicle) | DRUG | - |
| BPR277 ointment | DRUG | - |
| BPR277 | DRUG | - |
Inclusion Criteria: Part 1 Healthy volunteers * Healthy male and female subjects of non childbearing potential, 18 to 65 years of age inclusive and in good health Part 2 Patients with atopic dermatitis: * Male and female subjects, 18 to 65 years of age inclusive and having passed screening exami...
Top 20 of 26 competitors
BPR277 is an investigational small molecule developed by Novartis AG for topical treatment of atopic dermatitis. It is also known as BPR277 ointment (controlled application). The compound has been studied in a Phase 1 clinical trial that also included Netherton syndrome and healthy volunteers. BPR277 is not approved and remains in clinical development.
BPR277 is being studied for the topical treatment of atopic dermatitis, a chronic inflammatory skin condition. The Phase 1 trial of BPR277 also enrolled participants with Netherton syndrome and healthy volunteers. Because the program is at Phase 1, BPR277 has not been established as a treatment for atopic dermatitis and is not approved for any use.
BPR277 is developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the Phase 1 study of topical BPR277 in atopic dermatitis, Netherton syndrome, and healthy volunteers. No other developer is associated with the asset in the available program information.
BPR277 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The study was randomized, double-blind, and placebo-controlled, enrolling 12 participants. BPR277 is investigational and has not been approved by the FDA or any other regulator.
BPR277 has been evaluated in one completed Phase 1 trial, NCT01428297, titled A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome. The trial enrolled 12 participants across the United States and the Netherlands, included healthy volunteers, and used a randomized, double-blind, placebo-controlled design.
Yes. BPR277 ointment (controlled application) is another name for BPR277, the topical small molecule developed by Novartis AG. Both names refer to the same investigational compound studied in the completed Phase 1 trial NCT01428297 for atopic dermatitis, Netherton syndrome, and healthy volunteers.